By mid-2026 Bayer had settled roughly 100,000 Roundup lawsuits for about $11 billion, with per-plaintiff recoveries ranging from a few thousand dollars to several hundred thousand under a point-based allocation. This Roundup lawsuit settlement calculator applies the same structure Bayer used — severity of your non-Hodgkin lymphoma diagnosis, strength and length of glyphosate exposure, age, and litigation posture — to produce a 2026 estimate of what a Roundup claim may be worth. Enter your details below to see a low-to-high range. Because the settlement fund was allocated by points rather than a flat figure, a young, severely injured plaintiff with strong occupational exposure recovers many times more than a mild, poorly documented case.
Roundup, the glyphosate-based weed killer originally made by Monsanto (now owned by Bayer), is at the center of one of the largest mass-tort programs in U.S. history. Plaintiffs allege that long-term exposure caused non-Hodgkin lymphoma, and several juries returned large verdicts before Bayer agreed to a sweeping global settlement. Use the calculator below as a starting point, then read the detailed sections on the point system, eligibility, the science, taxation, and what is still happening in the litigation in 2026.
The calculator reflects the logic of Bayer's point-based settlement allocation. Instead of paying every claimant the same amount, the program weighed several factors to decide how much of the fund each plaintiff received. The calculator translates that into a transparent formula:
Estimate = Diagnosis Base × Exposure Factor × Age Factor × Litigation-Posture Factor + Documented Economic Loss
The diagnosis base reflects that aggressive subtypes such as diffuse large B-cell lymphoma are valued higher than milder, early-stage non-Hodgkin lymphoma in remission. The exposure factor rewards heavy, documented occupational exposure (farmers, landscapers, groundskeepers) over occasional home use, because stronger exposure evidence supports causation. The age factor increases value for younger claimants who lose more years of life and earnings. The litigation-posture factor recognizes that cases tried to verdict have produced larger numbers than the average mass-settlement allocation, though with far more risk and delay. Documented lost income and out-of-pocket medical costs are added on top.
Roundup recoveries fall into two very different buckets: the mass settlement allocations and the headline trial verdicts. The table below shows the figures commonly cited across the litigation. They are planning benchmarks, not guarantees.
| Recovery Type | Commonly Reported Range | Notes |
|---|---|---|
| Global settlement program (total) | ~$11 billion across ~100,000 cases | Point-based allocation |
| Blended per-plaintiff estimate | ~$100,000 – $160,000 | Wide variation by case strength |
| Lower-tier / milder cases | ~$5,000 – $50,000 | Limited exposure or mild disease |
| Trial verdicts (pre-appeal) | Tens of millions to hundreds of millions | Often reduced on appeal |
The enormous gap between the average allocation and the largest verdicts is the single most important thing to understand about Roundup compensation. A handful of plaintiffs won nine-figure jury awards (frequently reduced later), while the typical mass-settlement participant received a far smaller, point-weighted share. Your realistic estimate depends on where your case falls on that spectrum, which is exactly what the calculator's factors model.
Because tens of thousands of plaintiffs were resolved together, Bayer could not negotiate each case individually. Instead, the settlement used a point matrix that scored each claim on factors such as the type and severity of the non-Hodgkin lymphoma, the strength and duration of Roundup exposure, the claimant's age, the quality of the medical and exposure evidence, and whether the claimant had already been treated or had passed away. The total fund was then divided according to those points. The practical effect is that:
The calculator's exposure, age, and severity factors are a simplified stand-in for this matrix so you can see, directionally, how strongly each input moves the estimate.
Roundup claims center on a non-Hodgkin lymphoma diagnosis following meaningful glyphosate exposure. Qualifying subtypes commonly include diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, and chronic lymphocytic leukemia. Claimants typically fall into groups with substantial exposure:
Eligibility depends on the diagnosis, the strength and duration of exposure, and the statute of limitations in your state, which generally runs from the date of diagnosis or the date you reasonably connected the cancer to glyphosate. Because the rules and deadlines vary, an attorney experienced in Roundup litigation should review your exposure history and medical records.
Suppose a 60-year-old groundskeeper is diagnosed with moderate follicular non-Hodgkin lymphoma after years of occupational Roundup use, and joins the mass settlement. He has $40,000 in documented lost income and medical costs. Using the calculator: a moderate base of $120,000, heavy occupational exposure factor 1.4, age factor at 60 of about 1.05, mass-settlement posture 1.0, plus $40,000:
The range is intentionally wide because the point system itself produces a wide spread. If the same claimant were 45 instead of 60, the age factor would rise to about 1.20, pushing the central estimate higher; if exposure were only occasional, the factor would drop to 0.7 and the estimate would fall sharply.
The scientific debate is central to Roundup litigation. In 2015 the International Agency for Research on Cancer (IARC), part of the World Health Organization, classified glyphosate as probably carcinogenic to humans (Group 2A), citing limited evidence of an association with non-Hodgkin lymphoma. The U.S. Environmental Protection Agency, by contrast, concluded in its registration reviews that glyphosate is not likely to be carcinogenic to humans at label-compliant exposures, a position that has itself been challenged in court. Several U.S. juries weighed this conflicting evidence and found that Roundup exposure was a substantial contributing cause of plaintiffs' non-Hodgkin lymphoma, which drove the large early verdicts and ultimately the global settlement.
Under IRS Publication 4345, compensatory damages received on account of a personal physical injury or physical sickness — including cancer — are generally excluded from taxable income, covering medical expenses, pain and suffering, and emotional distress arising from the illness. However, punitive damages and interest are taxable, and Roundup verdicts in particular often included very large punitive components. Where a recovery blends compensatory and punitive elements, only the punitive and interest portions are generally taxable. Because the allocation can be complex, confirm the tax treatment of your specific Roundup settlement with a qualified tax professional.
Yes. While Bayer resolved a large block of claims through its global settlement, new lawsuits continued to be filed and tried in 2026, and the company pursued an appellate strategy arguing that federal pesticide-labeling law preempts state failure-to-warn claims — an issue that reached the higher courts. For individuals, the practical takeaway is that a qualifying non-Hodgkin lymphoma diagnosis with documented glyphosate exposure may still support a claim, but the statute of limitations in your state can bar a claim filed too late. Timely action and strong documentation remain essential.
By mid-2026, Bayer had reached settlements in roughly 100,000 Roundup lawsuits for a total of about $11 billion. Estimates of the average per-plaintiff payout vary widely with the source and the case mix, commonly cited between roughly $5,000 and $250,000, with one frequently quoted blended estimate around $100,000 to $160,000 per qualifying plaintiff. The wide spread exists because Bayer used a point-based allocation that pays catastrophically injured plaintiffs far more than mild cases, and a few trial verdicts ran into the hundreds of millions before reduction on appeal.
The calculator mirrors the structure of Bayer's point-based settlement: it starts from a base value tied to the severity of your non-Hodgkin lymphoma diagnosis, then adjusts for the strength and duration of your glyphosate/Roundup exposure, your age (younger claimants generally recover more for lost years), and a litigation-posture factor reflecting whether you are part of the mass settlement or in active trial litigation. It adds documented lost income and medical costs to produce a low-to-high estimate. It is educational only, not an offer from Bayer.
Roundup claims generally involve people diagnosed with non-Hodgkin lymphoma (including subtypes such as diffuse large B-cell lymphoma, follicular lymphoma, and chronic lymphocytic leukemia) after meaningful exposure to glyphosate-based Roundup, such as farmers, landscapers, groundskeepers, agricultural workers, and frequent home/garden users. Eligibility, exposure thresholds, and deadlines vary, so a qualified attorney should review your specific exposure history and diagnosis.
Rather than paying every plaintiff the same amount, Bayer's program assigned points based on factors such as the severity and type of cancer, the strength and length of Roundup exposure, the claimant's age, and the strength of the evidence. More points meant a larger share of the settlement fund. This is why a young plaintiff with severe, well-documented diffuse large B-cell lymphoma and decades of occupational exposure could recover many times more than an older plaintiff with a mild case and limited exposure proof.
Under IRS Publication 4345, compensatory damages received on account of a personal physical injury or physical sickness such as cancer are generally not taxable, including amounts for medical expenses and pain and suffering. However, punitive damages and interest are taxable, and Roundup verdicts in particular have included large punitive components. Confirm the tax treatment of your specific settlement with a tax professional.
Yes. Although Bayer resolved a large block of cases in its global settlement, new Roundup lawsuits continued to be filed and tried in 2026, and litigation over warning-label preemption reached the appellate courts. People with a qualifying non-Hodgkin lymphoma diagnosis and documented exposure may still have claims, subject to each state's statute of limitations measured from diagnosis or discovery of the link to glyphosate.
The International Agency for Research on Cancer (IARC), part of the World Health Organization, classified glyphosate as probably carcinogenic to humans (Group 2A) in 2015, citing limited evidence for non-Hodgkin lymphoma. The U.S. EPA has reached different conclusions in its registration reviews, and the scientific and regulatory debate is ongoing. Juries in several Roundup trials found that exposure was a substantial cause of plaintiffs' non-Hodgkin lymphoma.